Alkermes to Present Sustained Efficacy Data for Alixorexton in Narcolepsy Type 1
Phase 2 Vibrance-1 study extension shows sustained improvements in patient-reported disease severity, cognitive functioning, and fatigue.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
